18:45 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars...
18:26 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
23:28 , Jun 15, 2018 |  BC Extra  |  Clinical News

bluebird on track to submit MAA to EMA for LentiGlobin

bluebird bio Inc. (NASDAQ:BLUE) said it is on track to submit an MAA to EMA next half for its LentiGlobin BB305 to treat beta-thalassemia and reported additional data from three studies of the gene therapy....
11:34 , May 16, 2018 |  BC Innovations  |  Translation in Brief

Sickle cell strides

Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company...
20:55 , Dec 19, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method to rapidly mobilize donor HSCs from the bone marrow to the blood by antagonizing CXCR4 and agonizing CXCR2 could be useful for HSCTs. In mice, subcutaneous injection of the CXCR4...
00:08 , Dec 9, 2017 |  BC Extra  |  Preclinical News

A faster method for harvesting HSCs for transplantation

Researchers report a new two-drug regimen could speed up harvesting of hematopoietic stem cells for transplantation and yield a population of cells that engraft more efficiently than those produced by standard regimens. In a paper...
06:30 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

bluebird reports updated LentiGlobin data

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in 2 patients receiving the therapy in the open-label, U.S. Phase...
00:59 , Sep 2, 2017 |  BioCentury  |  Strategy

Pathfinding for access

A pact with the Centers for Medicare & Medicaid Services for Novartis AG ’s CAR T therapy demonstrates leadership in new value-based drug pricing models. Kymriah tisagenlecleucel represents a milestone for three reasons. Its approval...
07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: E selectin (SELE; CD62E); CXC chemokine receptor 4 (CXCR4; NPY3R)

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting SELE and/or CXCR4 could help prevent bone metastases of breast cancer. Levels of CXCR4 and several SELE ligands were higher in primary tumors from...
07:00 , Apr 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Integrin α9β1; integrin α4β1 (CD49D/CD29)

Hematology INDICATION: Bone marrow transplant (BMT) Mouse studies suggest dual inhibition of integrin α9β1 and integrin α4β1 in donors could help enhance the production of donor-derived hematopoietic stem cells (HSCs) used for BMT. In mice,...